Insights

Gathering insights about Elevation…

Similar companies to Elevation

Elevation Tech Stack

Elevation uses 8 technology products and services including MySQL, Google Fonts API, Handlebars, and more. Explore Elevation's tech stack below.

MySQL
Database
Google Fonts API
Font Scripts
Handlebars
Javascript Frameworks
jQuery Migrate
Javascript Libraries
Yoast SEO
Search Engines
HSTS
Security
reCAPTCHA
Security
X-Content-Type-Options
Web & Portal Technology

Media & News

HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Elevation Oncology, Inc. (NASDAQ: ELEV)
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Elevation Oncology, Inc. (NASDAQ: ELEV) related to its sale to Concentra Biosciences, LLC. Under the terms of the proposed transaction, Elevation shareholders will receive $0.36 in cash per share, plus one non-tradeable contingent value right representing the right to receive: (i) 100% of the closing net cash in excess of $26.4 million; and (ii) 80% of any net proceeds received within five years following closing from any disposition of EO-1022 that occurs within one year following closing. Is it a fair deal?
Jun 15, 2025 | www.globenewswire.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KNW, ELEV, CRKN on Behalf of Shareholders
NEW YORK , June 12, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Know Labs, Inc. (NYSE American: KNW)'s sale to Goldeneye 1995 LLC. If you are a Know Labs shareholder, click here to learn more about your legal rights and options.
Jun 12, 2025 | www.prnewswire.com
ELEVATION ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Elevation Oncology, Inc. - ELEV
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Elevation Oncology, Inc. (NasdaqCM: ELEV) to Concentra Biosciences, LLC. Under the terms of the proposed transaction, shareholders of Elevation will receive $0.36 in cash per share, plus one non-tradeable contingent value right representing the right to receive: (i) 100% of the closing net cash in e.
Jun 10, 2025 | www.businesswire.com
ELEV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Elevation Oncology, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Elevation Oncology, Inc. (NASDAQ: ELEV) to Concentra Biosciences, LLC is fair to Elevation shareholders. Under the terms of the proposed transaction, Elevation shareholders will receive $0.36 in cash per share, plus one non-tradeable contingent value right representing the right to receive: (i) 100% of the closing net cash in excess of $26.4 million; and (ii) 80% of any net proceeds re.
Jun 09, 2025 | www.businesswire.com
Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right
BOSTON , June 9, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that it has entered into a definitive merger agreement (the "Merger Agreement") with Concentra Biosciences, LLC ("Concentra"), whereby Concentra will acquire Elevation Oncology for $0.36 in cash per share of Elevation Oncology common stock ("Common Stock"), plus one non-tradeable contingent value right ("CVR"), which represents the right to receive: (i) 100% of the closing net cash in excess of $26.4 million; and (ii) 80% of any net proceeds received within five years following closing from any disposition of EO-1022 that occurs within one year following closing, each pursuant to the contingent value rights agreement (the "CVR Agreement"). The Elevation Oncology Board of Directors has unanimously determined that the acquisition by Concentra is in the best interests of all Elevation Oncology stockholders and has approved the Merger Agreement and related transactions.
Jun 09, 2025 | www.prnewswire.com
Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
-- Presented preclinical data for potentially differentiated HER3 ADC, EO-1022, at AACR Annual Meeting -- -- Expects to file IND application for EO-1022 in 2026 -- -- Cash runway into 2H 2026 -- BOSTON , May 15, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter ended March 31, 2025, and provided recent business updates. "We recently presented preclinical proof-of-concept data for EO-1022, reaffirming its potential as a differentiated HER3 ADC, and supporting our goal of providing a safer and more effective option for patients with HER3-expressing solid tumors," said Joseph Ferra, President and Chief Executive Officer of Elevation Oncology.
May 15, 2025 | www.prnewswire.com
Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
-- EO-1022 is a potentially differentiated HER3 ADC designed to address significant unmet needs across multiple solid tumors -- -- On-track to file IND application in 2026 -- BOSTON , April 25, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced new preclinical proof-of-concept data for its novel HER3 antibody-drug conjugate (ADC), EO-1022. The data will be presented in a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, being held April 25-30 in Chicago, Illinois.
Apr 25, 2025 | www.prnewswire.com

Elevation's Email Address Formats

Elevation uses at least 2 format(s):

Elevation Email Formats	Example	Percentage
First@elevationpartners.com.ph	John@elevationpartners.com.ph	93%
FirstLas@elevationpartners.com.ph	JohnDoe@elevationpartners.com.ph	7%

Frequently Asked Questions

Where is Elevation's headquarters located?

Elevation's main headquarters is located at 26th St., 1101 Taguig, Metro Manila 1634, PH. The company has employees across 3 continents, including AsiaEuropeNorth America.

What is Elevation's stock symbol?

Elevation is a publicly traded company; the company's stock symbol is ELEV.

What is Elevation's official website and social media links?

Elevation's official website is elevation.ph and has social profiles on LinkedIn.

What is Elevation's SIC code NAICS code?

Elevation's SIC code is 8742 - Management Consulting Services NAICS code is 541613 - Marketing Consulting Services.

How many employees does Elevation have currently?

As of October 2025, Elevation has approximately 30 employees across 3 continents, including AsiaEuropeNorth America. Key team members include Video Director: P. Z.Art Director: G. L.Accounts Manager: K. D.. Explore Elevation's employee directory with LeadIQ.

What industry does Elevation belong to?

Elevation operates in the Advertising Services industry.

What technology does Elevation use?

Elevation's tech stack includes MySQLGoogle Fonts APIHandlebarsjQuery MigrateYoast SEOHSTSreCAPTCHAX-Content-Type-Options.

What is Elevation's email format?

Elevation's email format typically follows the pattern of First@elevationpartners.com.ph. Find more Elevation email formats with LeadIQ.

When was Elevation founded?

Elevation was founded in 2013.

Elevation

Advertising ServicesPhilippines11-50 Employees

We know strategy and creativity go hand in hand. With our content creation capabilities, we develop compelling, human stories from start to finish. From startups to big players, brands can tell stories that matter. We believe in creativity for everyone.

Company Overview

Headquarters: 26th St., 1101 Taguig, Metro Manila 1634, PH
Website: elevation.ph
SIC Code: 8742 - Management Consulting Services
Stock Symbol: ELEV
NAICS Code: 541613 - Marketing Consulting Services
Founded: 2013
Employees: 11-50

Media & News

Funding & Financials

$1M$10M
Elevation's revenue is estimated to be in the range of $1M$10M

Funding & Financials

$1M$10M
Elevation's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Elevation

KKR

Francisco Partners

TA Associates

FTV Capital

Thoma Bravo

Insight Partners

Vitruvian Partners

The Riverside Company

Accel-KKR

Advent International

Summit Partners

Elevation Tech Stack

Media & News

HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Elevation Oncology, Inc. (NASDAQ: ELEV)

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KNW, ELEV, CRKN on Behalf of Shareholders

ELEVATION ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Elevation Oncology, Inc. - ELEV

ELEV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Elevation Oncology, Inc. Is Fair to Shareholders

Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right

Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025

Elevation's Email Address Formats

Frequently Asked Questions

Where is Elevation's headquarters located?

What is Elevation's stock symbol?

What is Elevation's official website and social media links?

What is Elevation's SIC code NAICS code?

How many employees does Elevation have currently?

What industry does Elevation belong to?

What technology does Elevation use?

What is Elevation's email format?

When was Elevation founded?

Elevation

Company Overview

Media & News

HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Elevation Oncology, Inc. (NASDAQ: ELEV)

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KNW, ELEV, CRKN on Behalf of Shareholders

ELEVATION ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Elevation Oncology, Inc. - ELEV

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?